Human Pancreatic Elastase

Total Page:16

File Type:pdf, Size:1020Kb

Human Pancreatic Elastase curopaiscnes Katentamt European Patent Office (jj) Publication number: O 1 98 645 B1 Office europeen des brevets cUHOPeAN PATENT SPECIFICATION © intci.*: C12N 15/57, C12N 9/66, 22.11.90 C07H 21/04, C12N1/20, Application number: 86302557.3 A61K 37/54 Date of filing: 07.04.86 jy nuinan pancreauc eiasiase. rropnetor: sankyo company LIMITED, 27.04.85 JP 91986/85 No. 1-6, 3-chome Nihonbashi Honcho Chuo-ku, 26.07.85 JP 163964/85 Tokyo(JP) 23.10.85 JP 236686/85 inventor: Takiguchi, Yo C/o Bio-Science Research Laboratory, Sankyo Company Limited 22.10.86 Bulletin 86/43 Mo. 2-58, 1-chome, Hiromachi Shinagawa-ku rokyo140(JP) Inventor: Tani, Tokyo C/o Bio-Science Research ui^nv/aLiui i ui ii ic yi ai u li ic Ljctlcl II. Laboratory, Sankyo Company Limited 22.11.90 Bulletin 90/47 Mo. 2-58, 1-chome, Hiromachi Shinagawa-ku rokyo 140(JP) nventor: Kawashima, Ichiro C/o Bio-Science Research -ab., Sankyo Company Limited No. 2-58, 1-chome, \T BE CH DE FR GB IT LI LU NL SE Hiromachi Shinagawa-ku Tokyo 140(JP) nventor: Eurukawa, Hidehiko C/o Bio-Science Research Lab., Sankyo Company Limited Ao. 2-58, 1-chome, Hiromachi IWIVI VI VSI IbU . Shinagawa-ku =P-A- 0157 604 rokyo 140(JP) nventor: Ohmine, Toshinori C/o Bio-Science Research -ab., Sankyo Company Limited No. 3I0CHIMICA ET BIOPHYSICA ACTA, vol. 623, no. 1, 2-58, 1-chome, u 1980 -iiromachi Shinagawa-ku Tokyo 140(JP) i/lay 29, (Amsterdam); C. LARGMAN ET nventor: Ohsumi, Jun C/o Bio-Science U.::"Human Pancreatic Proelastase 2 Sequence of the Research Lab., Vctivation Peptide", 208-212 Sankyo Company Limited No. 2-58, 1-chome, Hiromachi pp. Shinagawa-ku Tokyo 140(JP) 0 representative: Gibson, Christian John Robert et al, A ARKS & CLERK 57/60 Lincoln's Inn Fields, London VC2A3LS(GB) c iiiuiiuio iiuiii ii le puuuuaiion or me mention ot tne grant ot tne turopean patent, any person may give notice to le European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned tatement. It shall not be deemed to have been filed until the opposition fee has been paid (Art 99(1) European patent * c anvention). II- ACTORUM AG EP 0198 645 B1 uescription Background of the Invention 5 This invention relates to human pancreatic elastase. Elastase is a serine protease, capable of hydrolyzing the fibrous insoluble protein known as elastin. Elastin is a scleroprotein forming connective tissues, tendons, aortic integuments and cervical bundles of higher animals. Elastin is only slightly degraded by pepsin and trypsin. In the course of their study on arteriosclerosis, Balo' et ai observed degradation of the elastin fibers 10 of blood vessel walls, and postulated the presence of a degrading enzyme [Balo', J and Banga, I: Schweiz Z Pathol Bacteriol, 12, 350 (1949)]. Subsequently, Banga discovered an enzyme in the pancreas which specifically degrades elastin. The enzyme was isolated in the form of crystals and named "elastase" [Banga, I: Acta Physiol Acad Sci Hung, 3, 317 (1952)]. Elastase has been confirmed to exist in the pancreas of most animals, including humans, monkeys, 15 cats, rabbits, etc. The level is about 3.1 mg/g-pancreas in human beings, about 2.2 mg/g in bovine animals and about 10.2 mg/g in rats. A correlation is recognized between elastase activity and the age of a human being: a marked lowering in elastase activity is observed in the pancreas and plasma of males over 40 and females over 60 years [Loeven, W A and Baldwin, Maureen M: Gerontologia, 17, 170 (1971)]. In the case of patients with arteriosclerosis, the elastase activity in the pancreas was found to be 20 markedly lower than that of healthy people, and in some cases it had completely disappeared [Balo', J, and Banga, I: Nature, 178, 310 (1956)]. Subsequent studies have also demonstrated that elastase not on- ly degrades elastin but also promotes elastin biosynthesis. Studies on the pharmacological action of elastase have been carried out in rats and rabbits, and have revealed the following effects: 25 1) inhibition of the deposition of lipids and calcium on arterial walls; 2) elimination of cholesterol and calcium from arterial walls; 3) selective degradation of denatured elastin; 4) promotion of synthesis of elastin fibers in the arterial walls; 30 5) lowering of serum lipids; 6) improvement of lipoprotein metabolism. In clinical studies conducted on the basis of the studies mentioned above, the following effects have become apparent after oral administration of elastase: 35 1) restoration of elasticity and expandability of arterial walls; 2) improvement of serum lipid abnormality; 3) improvement of serum lipoprotein metabolism. 40 Elastase extracted and purified from porcine pancreas was used for the above studies. However, with administration of porcine elastase to human beings, there is the risk of antibody formation due to the foreign protein, and the danger of anaphylaxis with repeated administration (Japanese Patent Applica- tion Laid-open 11180/1984). Accordingly, human elastase is preferable for human use. However it has been extremely difficult to procure human elastase in sufficient quantities from traditional sources. 45 At present, two kinds of human pancreatic elastase are known, elastase 1 and elastase 2. They have not been fully characterized. For example, for pancreatic elastase 2, a partial sequence of 16 amino acid residues representing 12 amino acid residues in the activation peptide and 4 amino acid residues at the N-terminal end of the elastase have been sequenced [Largman, C et al; Biochim Biophys Acta, 623, 208 (1 980)]. This partial sequence is Cys Gly Asp Pro Thr Tyr Pro Pro Tyr Val Thr Arg Val Val Gly Gly. Objects of the Present Invention It is an object of this invention to make human pancreatic elastase more readily available, with the pos- sibility of obtaining the elastase in substantially pure form. It is a further object of this invention to elimi- 55 nate the continuing dependency on human pancreas for adequate supplies of human pancreatic elastase. It is a yet further object to produce new elastase compounds and elastase-like compounds. Summary of the Present Invention 30 This invention embraces the use of genetic engineering for the production of human pancreatic elastase. Recombinant DNA technology is employed, in order to provide a base sequence coding for a human pancreatic elastase or a functionally similar compound. Correspondingly, human pancreatic elastase and functionally similar compounds now become readily available for the first time. Indeed, nov- el elastases have been discovered and are part of this invention. 35 More specifically, this invention provides a compound which includes an amino acid sequence for a EP0 198 645 B1 human pancreatic elastase selected from the group of human pancreatic elastase IIB, human pancreatic elastase IMA, human pancreatic elastase NIB, and any compounds corresponding to human pancreatic elastase IIB, IIIA or NIB with one or more deleted, inserted, replaced or altered amino acids. The se- quences for human pancreatic elastases IIB, IIIA, and IIB are given below. The present invention also 5 embraces DNA which codes for the compounds provided by this invention. Thus, through the use of genetic engineering, it is now possible in accordance with the present inven- tion to provide a DNA which codes for a compound capable of functioning as a human pancreatic elastase. Novel human pancreatic elastases are provided, as well as derivative compounds which func- tion as human pancreatic elastases. Such compounds, which include compounds arising from silent muta- 10 tions, fusion proteins and other compounds functionally effective as a human pancreatic elastase, are included. Thus, substantially similar protein effective as a human pancreatic elastase, that is, com- pounds corresponding to human pancreatic elastases with one or more deleted, replaced or altered ami- no acids, and compounds corresponding to human pancreatic elastases with one or more extra amino ac- ids, are also included. More especially, precursor compounds such as proelastases and preproelastas- 15 es, especially when expressed by a recombinant DNA sequence, as well as elastases obtained by activation of such precursor compounds, are part of this invention. Further examples of precursor com- pounds within this invention include fusion proteins comprising an elastase (optionally in the form of a proelastase or preproelastase) and an amino acid sequence derived from another protein. In particular, such fusion proteins can be obtained when the DNA coding for an elastase is inserted into an expres- 20 sion gene downstream of a promoter. Elastase IIB This invention provides human pancreatic elastase IIB having the following amino acid sequence of 25 formula (III): (N)-Cys Gly Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gin Val Ser Leu Gin Tyr Ser Ser Asn Gly Gin Trp Tyr His 30 Thr Cys Gly Gly Ser Leu lie Ala Asn Ser Trp Val Leu Thr Ala Ala His Cys He Ser Ser Ser Arg lie Tyr Arg Val Met Leu Gly Gin His Asn Leu Tyr Val Ala Glu Ser Gly Ser Leu Ala Val Ser Val Ser Lys lie Val 35 Val His Lys Asp Trp Asn Ser Asn Gin Val Ser Lys Gly Asn Asp He Ala Leu Leu Lys Leu Ala Asn Pro Val Ser Leu Thr Asp Lys He Gin Leu Ala Cys Leu Pro Pro Ala Gly Thr He Leu Pro Asn Asn Tyr Pro Cys Tyr 40 Val Thr Gly Trp Gly Arg Leu Gin Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gin Gly Arg Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp Gly Ser Thr Val Lys Thr Asn Met He Cys Ala Gly Gly Asp 45 Gly Val lie Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gin Ala Ser Asp Gly Arg Trp Glu Val His Gly lie Gly Ser Leu Thr Ser Val Leu Gly Cys Asn Tyr Tyr Tyr Lys Pro Ser He Phe Thr Arg Val Ser 50 Asn Tyr Asn Asp Trp He Asn Ser Val lie Ala Asn Asn - (C) For the human pancreatic elastase IIB itself, the N-terminal end simply terminates with a hydrogen at- om.
Recommended publications
  • The Secretory Proprotein Convertase Neural Apoptosis-Regulated Convertase 1 (NARC-1): Liver Regeneration and Neuronal Differentiation
    The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation Nabil G. Seidah*†, Suzanne Benjannet*, Louise Wickham*, Jadwiga Marcinkiewicz*, Ste´phanie Be´langer Jasmin‡, Stefano Stifani‡, Ajoy Basak§, Annik Prat*, and Michel Chre´ tien§ *Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, QC, H2W 1R7 Canada; ‡Montreal Neurological Institute, McGill University, Montreal, QC, H3A 2B4 Canada; and §Regional Protein Chemistry Center and Diseases of Aging Unit, Ottawa Health Research Institute, Ottawa Hospital, Civic Campus, 725 Parkdale Avenue, Ottawa, ON, K1Y 4E9 Canada Edited by Donald F. Steiner, University of Chicago, Chicago, IL, and approved December 5, 2002 (received for review September 10, 2002) Seven secretory mammalian kexin-like subtilases have been iden- LP251 (Eli Lilly, patent no. WO 02͞14358 A2) recently cloned tified that cleave a variety of precursor proteins at monobasic and by two pharmaceutical companies. NARC-1 was identified via dibasic residues. The recently characterized pyrolysin-like subtilase the cloning of cDNAs up-regulated after apoptosis induced by SKI-1 cleaves proproteins at nonbasic residues. In this work we serum deprivation in primary cerebellar neurons, whereas LP251 describe the properties of a proteinase K-like subtilase, neural was discovered via global cloning of secretory proteins. Aside apoptosis-regulated convertase 1 (NARC-1), representing the ninth from the fact that NARC-1 mRNA is expressed in liver ϾϾ member of the secretory subtilase family. Biosynthetic and micro- testis Ͼ kidney and that the gene localizes to human chromo- sequencing analyses of WT and mutant enzyme revealed that some 1p33-p34.3, no information is available on NARC-1 ac- human and mouse pro-NARC-1 are autocatalytically and intramo- tivity, cleavage specificity, cellular and tissue expression, and lecularly processed into NARC-1 at the (Y,I)VV(V,L)(L,M)2 motif, a biological function.
    [Show full text]
  • Chymotrypsin-Like Peptidases in Insects
    Chymotrypsin-like peptidases in insects Dissertation zur Erlangung des akademischen Grades Doctor rerum naturalium (Dr. rer. nat.) Fachbereich Biologie/Chemie der Universität Osnabrück vorgelegt von Gunnar Bröhan Osnabrück, Mai 2010 TABLE OF CONTENTS I Table of contents 1. Introduction 1 1.1. Serine endopeptidases 1 1.2. The structure of S1A chymotrypsin-like peptidases 2 1.3. Catalytic mechanism of chymotrypsin-like peptidases 6 1.4. Insect chymotrypsin-like peptidases 9 1.4.1. Chymotrypsin-like peptidases in insect immunity 9 1.4.2. Role of chymotrypsin-like peptidases in digestion 14 1.4.3. Involvement of chymotrypsin-like peptidases in molt 16 1.5. Objective of the work 18 2. Material and Methods 20 2.1. Material 20 2.1.1. Culture Media 20 2.1.2. Insects 20 2.2. Molecular biological methods 20 2.2.1. Tissue preparations for total RNA isolation 20 2.2.2. Total RNA isolation 21 2.2.3. Reverse transcription 21 2.2.4. Quantification of nucleic acids 21 2.2.5. Chemical competent Escherichia coli 21 2.2.6. Ligation and transformation in E. coli 21 2.2.7. Preparation of plasmid DNA 22 2.2.8. Restriction enzyme digestion of DNA 22 2.2.9. DNA gel-electrophoresis and DNA isolation 22 2.2.10. Polymerase-chain-reaction based methods 23 2.2.10.1. RACE-PCR 23 2.2.10.2. Quantitative Realtime PCR 23 2.2.10.3. Megaprimer PCR 24 2.2.11. Cloning of insect CTLPs 25 2.2.12. Syntheses of Digoxigenin-labeled DNA and RNA probes 26 2.2.13.
    [Show full text]
  • Structure of the Human Signal Peptidase Complex Reveals the Determinants for Signal Peptide Cleavage
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.11.378711; this version posted November 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Structure of the Human Signal Peptidase Complex Reveals the Determinants for Signal Peptide Cleavage A. Manuel Liaci1, Barbara Steigenberger2,3, Sem Tamara2,3, Paulo Cesar Telles de Souza4, Mariska Gröllers-Mulderij1, Patrick Ogrissek1,5, Siewert J. Marrink4, Richard A. Scheltema2,3, Friedrich Förster1* Abstract The signal peptidase complex (SPC) is an essential membrane complex in the endoplasmic reticulum (ER), where it removes signal peptides (SPs) from a large variety of secretory pre-proteins with exquisite specificity. Although the determinants of this process have been established empirically, the molecular details of SP recognition and removal remain elusive. Here, we show that the human SPC exists in two functional paralogs with distinct proteolytic subunits. We determined the atomic structures of both paralogs using electron cryo- microscopy and structural proteomics. The active site is formed by a catalytic triad and abuts the ER membrane, where a transmembrane window collectively formed by all subunits locally thins the bilayer. This unique architecture generates specificity for thousands of SPs based on the length of their hydrophobic segments. Keywords Signal Peptidase Complex, Signal Peptide, Protein Maturation, Membrane Thinning, cryo-EM, Crosslinking Mass Spectrometry, Molecular Dynamics Simulations, Protein Secretion, ER Translocon 1Cryo-Electron Microscopy, Bijvoet Centre for Biomolecular Research, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.
    [Show full text]
  • Trypsinogen Isoforms in the Ferret Pancreas Eszter Hegyi & Miklós Sahin-Tóth
    www.nature.com/scientificreports OPEN Trypsinogen isoforms in the ferret pancreas Eszter Hegyi & Miklós Sahin-Tóth The domestic ferret (Mustela putorius furo) recently emerged as a novel model for human pancreatic Received: 29 June 2018 diseases. To investigate whether the ferret would be appropriate to study hereditary pancreatitis Accepted: 25 September 2018 associated with increased trypsinogen autoactivation, we purifed and cloned the trypsinogen isoforms Published: xx xx xxxx from the ferret pancreas and studied their functional properties. We found two highly expressed isoforms, anionic and cationic trypsinogen. When compared to human cationic trypsinogen (PRSS1), ferret anionic trypsinogen autoactivated only in the presence of high calcium concentrations but not in millimolar calcium, which prevails in the secretory pathway. Ferret cationic trypsinogen was completely defective in autoactivation under all conditions tested. However, both isoforms were readily activated by enteropeptidase and cathepsin B. We conclude that ferret trypsinogens do not autoactivate as their human paralogs and cannot be used to model the efects of trypsinogen mutations associated with human hereditary pancreatitis. Intra-pancreatic trypsinogen activation by cathepsin B can occur in ferrets, which might trigger pancreatitis even in the absence of trypsinogen autoactivation. Te digestive protease precursor trypsinogen is synthesized and secreted by the pancreas to the duodenum where it becomes activated to trypsin1. Te activation process involves limited proteolysis of the trypsinogen activation peptide by enteropeptidase, a brush-border serine protease specialized for this sole purpose. Te activation peptide is typically an eight amino-acid long N-terminal sequence, which contains a characteristic tetra-aspartate motif preceding the activation site peptide bond, which corresponds to Lys23-Ile24 in human trypsinogens.
    [Show full text]
  • Role of the Amino Terminus in Intracellular Protein Targeting to Secretory Granules Teresa L
    In Vitro Mutagenesis of Trypsinogen: Role of the Amino Terminus in Intracellular Protein Targeting to Secretory Granules Teresa L. Burgess,* Charles S. Craik,** Linda Matsuuchi,* and Regis B. Kelly* * Department of Biochemistry and Biophysics, and *Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143 Abstract. The mouse anterior pituitary tumor cell expressed in AtT-20 cells to determine whether intra- line, AtT-20, targets secretory proteins into two distinct cellular targeting could be altered. Replacing the tryp- intracellular pathways. When the DNA that encodes sinogen signal peptide with that of the kappa-immu- trypsinogen is introduced into AtT-20 cells, the protein noglobulin light chain, a constitutively secreted is sorted into the regulated secretory pathway as protein, does not alter targeting to the regulated secre- efficiently as the endogenous peptide hormone ACq'H. tory pathway. In addition, deletion of the NH2-terminal In this study we have used double-label immunoelec- "pro" sequence of trypsinogen has virtually no effect tron microscopy to demonstrate that trypsinogen on protein targeting. However, this deletion does affect colocalizes in the same secretory granules as ACTH. the signal peptidase cleavage site, and as a result the In vitro mutagenesis was used to test whether the in- enzymatic activity of the truncated trypsin protein is formation for targeting trypsinogen m the secretory abolished. We conclude that neither the signal peptide granules resides at the amino (NH2) terminus of the nor the 12 NH2-terminal amino acids of trypsinogen protein. Mutations were made in the DNA that en- are essential for sorting to the regulated secretory codes trypsinogen, and the mutant proteins were pathway of AtT-20 cells.
    [Show full text]
  • Chem331 Tansey Chpt4
    3/10/20 Adhesion Covalent Cats - Proteases Roles Secretion P. gingivalis protease signal peptidases Immune Development Response T-cell protease matriptase 4 classes of proteases: Serine, Thiol (Cys), Acid Blood pressure Digestion regulation (Aspartyl), & Metal (Zn) trypsin renin Function Protease ex. Serine Cysteine trypsin, subtilisin, a-lytic Complement protease protease Nutrition Cell fusion protease Fixation hemaglutinase Invasion matrixmetalloproteases CI protease Evasion IgA protease Reproduction Tumor ADAM (a disintegrain and Invasion Adhesion collagenase and metalloproteinase) Fertilization signal peptidase, viral Processing acronase proteases, proteasome Signaling caspases, granzymes Fibrinolysis Pain Sensing tissue plasminogen kallikrein Acid Metallo- actvator protease protease Animal Virus Hormone Replication Processing HIV protease Kex 2 Substrate Specificity Serine Proteases Binding pocket is responsible for affinity Ser, His and Asp in active site Ser Proteases Multiple Mechanism Chymotrypsin Mechanism •Serine not generally an active amino acid for acid/base catalysis Nucleophilic attack •Catalytic triad of serine, histadine and aspartate responsible for the reactivity of serine in this active site •Covalent catalysis, Acid/base Catalysis, transition state bindingand Proximity mechanisms are used •Two phase reaction when an ester is used – burst phase - E +S initial reactions – steady state phase - EP -> E + P (deacylation) – The first step is the covalent catalysis - where the substrate actually is bound to the enzyme itself
    [Show full text]
  • Proteolytic Cleavage—Mechanisms, Function
    Review Cite This: Chem. Rev. 2018, 118, 1137−1168 pubs.acs.org/CR Proteolytic CleavageMechanisms, Function, and “Omic” Approaches for a Near-Ubiquitous Posttranslational Modification Theo Klein,†,⊥ Ulrich Eckhard,†,§ Antoine Dufour,†,¶ Nestor Solis,† and Christopher M. Overall*,†,‡ † ‡ Life Sciences Institute, Department of Oral Biological and Medical Sciences, and Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada ABSTRACT: Proteases enzymatically hydrolyze peptide bonds in substrate proteins, resulting in a widespread, irreversible posttranslational modification of the protein’s structure and biological function. Often regarded as a mere degradative mechanism in destruction of proteins or turnover in maintaining physiological homeostasis, recent research in the field of degradomics has led to the recognition of two main yet unexpected concepts. First, that targeted, limited proteolytic cleavage events by a wide repertoire of proteases are pivotal regulators of most, if not all, physiological and pathological processes. Second, an unexpected in vivo abundance of stable cleaved proteins revealed pervasive, functionally relevant protein processing in normal and diseased tissuefrom 40 to 70% of proteins also occur in vivo as distinct stable proteoforms with undocumented N- or C- termini, meaning these proteoforms are stable functional cleavage products, most with unknown functional implications. In this Review, we discuss the structural biology aspects and mechanisms
    [Show full text]
  • Intrinsic Evolutionary Constraints on Protease Structure, Enzyme
    Intrinsic evolutionary constraints on protease PNAS PLUS structure, enzyme acylation, and the identity of the catalytic triad Andrew R. Buller and Craig A. Townsend1 Departments of Biophysics and Chemistry, The Johns Hopkins University, Baltimore MD 21218 Edited by David Baker, University of Washington, Seattle, WA, and approved January 11, 2013 (received for review December 6, 2012) The study of proteolysis lies at the heart of our understanding of enzyme evolution remain unanswered. Because evolution oper- biocatalysis, enzyme evolution, and drug development. To un- ates through random forces, rationalizing why a particular out- derstand the degree of natural variation in protease active sites, come occurs is a difficult challenge. For example, the hydroxyl we systematically evaluated simple active site features from all nucleophile of a Ser protease was swapped for the thiol of Cys at serine, cysteine and threonine proteases of independent lineage. least twice in evolutionary history (9). However, there is not This convergent evolutionary analysis revealed several interre- a single example of Thr naturally substituting for Ser in the lated and previously unrecognized relationships. The reactive protease catalytic triad, despite its greater chemical similarity rotamer of the nucleophile determines which neighboring amide (9). Instead, the Thr proteases generate their N-terminal nu- can be used in the local oxyanion hole. Each rotamer–oxyanion cleophile through a posttranslational modification: cis-autopro- hole combination limits the location of the moiety facilitating pro- teolysis (10, 11). These facts constitute clear evidence that there ton transfer and, combined together, fixes the stereochemistry of is a strong selective pressure against Thr in the catalytic triad that catalysis.
    [Show full text]
  • Specific, Gene Expression Signatures in HIV-1 Infection1
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Qingsheng Li Publications Papers in the Biological Sciences 2009 Microarray Analysis of Lymphatic Tissue Reveals Stage- Specific, Gene Expression Signatures in HIV-1 Infection1 Qingsheng Li University of Minnesota, [email protected] Anthony J. Smith University of Minnesota Timothy W. Schacker University of Minnesota John V. Carlis University of Minnesota Lijie Duan University of Minnesota See next page for additional authors Follow this and additional works at: https://digitalcommons.unl.edu/biosciqingshengli Li, Qingsheng; Smith, Anthony J.; Schacker, Timothy W.; Carlis, John V.; Duan, Lijie; Reilly, Cavan S.; and Haase, Ashley T., "Microarray Analysis of Lymphatic Tissue Reveals Stage- Specific, Gene Expression Signatures in HIV-1 Infection1" (2009). Qingsheng Li Publications. 8. https://digitalcommons.unl.edu/biosciqingshengli/8 This Article is brought to you for free and open access by the Papers in the Biological Sciences at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Qingsheng Li Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Authors Qingsheng Li, Anthony J. Smith, Timothy W. Schacker, John V. Carlis, Lijie Duan, Cavan S. Reilly, and Ashley T. Haase This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/ biosciqingshengli/8 NIH Public Access Author Manuscript J Immunol. Author manuscript; available in PMC 2013 January 23. Published in final edited form as: J Immunol. 2009 August 1; 183(3): 1975–1982. doi:10.4049/jimmunol.0803222. Microarray Analysis of Lymphatic Tissue Reveals Stage- Specific, Gene Expression Signatures in HIV-1 Infection1 $watermark-text $watermark-text $watermark-text Qingsheng Li2,*, Anthony J.
    [Show full text]
  • Tryptic Dissection and Reconstitution of Translocation Activity for Nascent Presecretory Proteins Across Microsomal Membranes
    Proc. Natd. Acad. Sci. USA Vol. 76, No. 4, pp. 1795-1799, April 1979 Cell Biology Tryptic dissection and reconstitution of translocation activity for nascent presecretory proteins across microsomal membranes (prolactin mRNA/translation in reticulocyte lysate/signal and ribosome receptor domain/transport domain/signal peptidase) PETER WALTER, ROBERT C. JACKSON*, MADELEINE M. MARCUS, VISHWANATH R. LINGAPPA, AND GUNTER BLOBEL Laboratory of Cell Biology, The Rockefeller University, New York, New York 10021 Communicated by Fritz Lipmann, December 26,1978 ABSTRACT The ability of microsomal membranes to tionally competent components which were separated by translocate nascent presecretory proteins across their lipid bi- centrifugation. Translocation activity of the membrane can be layer into the intravesicular space was investigated by using regenerated by recombination of the fractions. trypsin as a proteolytic probe. We found that under defined conditions trypsin is able to dissect the translocation activity METHODS of microsomal membranes into components that can be sepa- rated into two fractions, one soluble and the other membrane Preparation of Stripped Microsomal Membranes. Rough bound. The trypsinized membrane fraction has lost its translo- microsomal membranes were prepared from freshly excised cation activity. Addition of the trypsin-generated soluble frac- dog pancreas (11) as described (12), with the following excep- tion, however, results in reconstitution of translocation activity. tions: all buffers contained 1 mM dithiothreitol and the rough These results are compatible with the notion proposed in the microsomes were collected by centrifugation for 2.5 hr at signal hypothesis that the translocation activity of the micro- somal membrane resides in transmembrane protein(s). We 140,000 X gay.
    [Show full text]
  • The Role of Elastases in Pancreatic Diseases
    The role of elastases in pancreatic diseases Ph.D. Thesis Anna Zsófia Tóth M.D. Supervisors: Prof. Péter Hegyi, M.D., Ph D., D.Sc. Prof. Miklós Sahin-Tóth, M.D., Ph.D., D.Sc Doctoral School of Theoretical Medicine Szeged 2018. Content Content ....................................................................................................................................... 1 1. List of abbreviations ........................................................................................................... 3 2. Introduction ......................................................................................................................... 5 2.1. Exocrin pancreatic insufficiency ................................................................................. 5 2.2. Pancreatic elastases ...................................................................................................... 5 2.3. Pancreatic function tests based on detection of elastases ............................................ 7 2.4. Possible role of elastases in chronic pancreatitis ......................................................... 8 3. Aims .................................................................................................................................. 10 3.1. ScheBo Pancreatic Elastase 1 Test Study .................................................................. 10 3.2. Genetic analysis study ............................................................................................... 10 4. Materials and methods .....................................................................................................
    [Show full text]
  • Proline Residues in the Maturation and Degradation of Peptide Hormones and Neuropeptides
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Volume 234, number 2, 251-256 FEB 06071 July 1988 Review Letter Proline residues in the maturation and degradation of peptide hormones and neuropeptides Rolf Mentlein Anatomisches Institut der Christian-Albrechts Universitiit zu Kiel, OlshausenstraJe 40.2300 Kiel I, FRG Received 4 May 1988; revised version received 23 May 1988 The proteases involved in the maturation of regulatory peptides like those of broader specificity normally fail to cleave peptide bonds linked to the cyclic amino acid proline. This generates several mature peptides with N-terminal X-Pro- sequences. However, in certain non-mammalian tissues repetitive pre-sequences of this type are removed by specialized dipeptidyl (amino)peptidases during maturation. In mammals, proline-specific proteases are not involved in the biosyn- thesis of regulatory peptides, but due to their unique specificity they could play an important role in the degradation of them. Evidence exists that dipeptidyl (amino)peptidase IV at the cell surface of endothelial cells sequesters circulating peptide hormones which arc then susceptible to broader aminopeptidase attack. The cleavage of several neuropeptides by prolyl endopeptidase has been demonstrated in vitro, but its role in the brain is questionable since the precise localiza- tion of the protease is not clarified. Neuropeptide; Peptide hormone; Proteolytic processing; Degradation; Dipeptidyl (amino)peptidase; Prolyl endopeptidase 1. INTRODUCTION 2. DIRECTION OF THE PROTEOLYTIC MATURATION OF REGULATORY The unique cyclic and imino structure of the PEPTIDES BY PROLINE RESIDUES amino acid proline influences not only the confor- mation of peptide chains, but also restricts the at- Regulatory peptides are synthesized as part of tack of proteases.
    [Show full text]